<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287495</url>
  </required_header>
  <id_info>
    <org_study_id>060083</org_study_id>
    <secondary_id>06-C-0083</secondary_id>
    <nct_id>NCT00287495</nct_id>
    <nct_alias>NCT00304122</nct_alias>
  </id_info>
  <brief_title>BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma</brief_title>
  <official_title>Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Kaposi's sarcoma (KS) is a disease in which cancer cells are found in the tissues under
           the skin or mucous membranes that line the mouth, nose, and anus. KS causes red or
           purple patches (lesions) on the skin or mucous membranes and spreads to other organs in
           the body, such as the lungs, liver, or intestinal tract.

        -  BAY 43-9006 inhibits the activity of several proteins or protein receptors in cells that
           are thought to be important to the progression of KS. Blocking these mechanisms may
           cause KS to get better.

      Objectives:

        -  To learn about the toxicity and blood levels of BAY 43-9006 in people with KS who are
           and are not taking the anti-retroviral drug ritonavir.

        -  To look for evidence of a beneficial treatment effect of BAY 43-9006

      Eligibility:

        -  Adults with confirmed KS, both HIV-positive and HIV-negative.

        -  Patients must have either 1) at least five measurable KS lesions with no previous local
           therapy, or 2) other measurable non-skin disease that permits evaluation of a response
           to treatment.

      Design:

        -  Patients are randomly assigned to a specific dose of BAY 43-9006. They take the drug by
           mouth either once or twice daily, depending on their dose group, for up to 54 weeks.

        -  Drug blood levels are determined after patients have been taking BAY 43-9006 for 1 to 2
           weeks by blood collections immediately before the dose and at 1, 2, 4, 8, 12, 16 and 24
           hours after the dose.

        -  Patients are evaluated every 3 weeks with review of a medication diary, interview about
           drug side effects, physical examination, and assessment of KS lesions.

        -  KS lesions are photographed on entering the study and at other time points during the
           study.

        -  CD4 cell counts and HIV viral load are tested every 12 weeks.

        -  Biopsies are done at the start of the study, on day 15, and if it appears that all of
           the lesions have resolved.

        -  Other procedures, such as CT or MRI scans, may be done if medically indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: This study is designed to test the toxicity and pharmacokinetics of different
      doses of BAY 43-9006 (Sorafenib) in patients with Kaposi s sarcoma (KS). It will also assess,
      in a preliminary manner, the activity of BAY 43-9006 in this disease and its effect on
      biological markers. BAY 43-9006 is a potent inhibitor of wild-type and mutant c-Raf kinase
      isoforms. In addition, this agent also inhibits p38, c-kit, vascular endothelial growth
      factor receptor 2(VEGFR2), VEGF-R3, and platelet derived growth factor receptor beta
      (PDGFR-B). There is evidence that several of these receptors, and especially VEGF-R2,
      VEGF-R3, and PDGF-RB, are important in KS pathogenesis. The principle tumor cells of KS
      lesions are spindle cells, which are derived from endothelial cells. Spindle cells
      proliferate in response to VEGF, VEGF-C (a ligand for VEGF-R3), and PDGF, and the stimulation
      of spindle cells by these factors appears to be an important component in the pathogenesis of
      KS. There is also evidence that c-kit is important in KS. Because BAY 43-9006 can inhibit the
      function of these receptors and c-kit, it may have specific activity against this tumor. BAY
      43-9006 is metabolized at least in part by CYP 3A4, and ritonavir, an HIV protease inhibitor
      commonly used in AIDS patients, is an inhibitor of CYP 3A4. Also, AIDS patients are often
      quite sensitive to drug toxicities. Thus, patients with AIDS-KS on ritonavir may be
      particularly sensitive to BAY 43-9006.

      OBJECTIVES: To assess the toxicity profile and pharmacokinetics of BAY 43-9006 at oral dose
      regimens of 200 mg once daily, 200mg twice daily, or 400 mg twice daily, up to the toxic
      dose, in patients with HIV-associated Kaposi s sarcoma (KS) who are receiving ritonavir.
      Also, to assess in a preliminary manner the pharmacokinetics and toxicity profile of BAY
      43-9006 in patients who are not receiving ritonavir.

      ELIGIBILITY: Key eligibility criteria are as follows: patients 18 years of age or older, with
      or without HIV infection, and with KS and at least 5 cutaneous lesions untreated by local
      therapy; patients with HIV infection must have KS that is progressing or stable on highly
      active antiretroviral therapy (HAART); patients with extensive active, visceral, or
      symptomatic KS are excluded.

      DESIGN: Patients with AIDS-KS who are receiving ritonavir will be administered BAY 43-9006.
      An initial group of patients will be administered 200 mg BAY 43-9006 once daily, and
      subsequent groups will receive 200 mg twice daily and 400 mg twice daily respectively. Also
      two groups of patients with KS and not on ritonavir will be administered 200 mg and 400 mg
      BAY 43-9006 twice daily respectively. Patients will be studied for toxicity,
      pharmacokinetics, KS response, the effect on biological markers such as target receptor
      kinase phosphorylation and signaling molecules in KS tissue. Other parameters that will be
      assessed will include VEGF levels, the viral load of KSHV, and KS lesion blood flow by
      non-invasive techniques. If patients tolerate BAY 43-9006, they will receive it for up to 24
      weeks. If they have evidence of stable KS or a tumor response, they may receive the drug for
      up to 54 weeks total.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2, 2006</start_date>
  <completion_date type="Actual">October 18, 2017</completion_date>
  <primary_completion_date type="Actual">September 21, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess toxicity profile and pharmacokinetics of BAY 43-9006</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Kaposi's Sarcoma</condition>
  <condition>HHV-8</condition>
  <condition>KSHV</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 43-9006</intervention_name>
    <description>BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age 18 years or greater.

               2. Kaposi's sarcoma (KS) pathologically confirmed by CCR Pathology. Patients with
                  both HIV-associated and HIV-negative KS will be eligible.

               3. Either (1) at least 5 measurable cutaneous KS lesions with no previous local
                  therapy, or (2) other measurable non-cutaneous disease that permits a response to
                  be assessed.

               4. Patients with HIV-related KS must be receiving and be willing to comply with a
                  regimen of highly active antiretroviral therapy (HAART) consistent with DHHS
                  treatment guidelines that either (1) utilizes 3 or more drugs or (2) attains
                  suppression of HIV below the limit of detection (50 copies HIV/ml using Roche
                  Amplicor Monitor assay or similar standard test).

               5. For patients with HIV-associated KS, KS lesions must either (1) be increasing
                  during the 3 months prior to screening while the patient is receiving HAART or
                  has unchanged suppression of HIV to below the limits of detection; or (2) must be
                  stable for at least four months while the patient is taking highly active
                  antiretroviral therapy (HAART).

               6. ECOG performance status less than or equal to 2

               7. Life expectancy greater than 6 months

               8. The following hematologic parameters:

          -  Hemoglobin greater than 9 g/l

          -  WBC greater than 1000/mm(3)

          -  Platelets greater than 75,000/mm(3)

          -  PT and PTT less than or equal to 120% of control, unless the patient has the presence
             of a lupus anticoagulant

        The following hepatic parameters:

          -  For patients not receiving protease inhibitor therapy: bilirubin less than or equal to
             1.5 times the upper limit of normal (ULN). For patients receiving protease inhibitor
             therapy and for whom the elevated bilirubin is felt to be related to this therapy
             total bilirubin should be less than or equal to 3.7 mg/dl with a direct fraction less
             than or equal to 0.2 mg/dl.

          -  AST/GOT less than or equal to 2.5 times the ULN

          -  Either serum creatinine less than or equal to 1.5 mg/dl or measured creatinine
             clearance greater than 60 mL/min.

          -  Patients must be willing to use effective birth control.

        EXCLUSION CRITERIA:

          1. Patients with extensive active or symptomatic pulmonary KS

          2. Patients with symptomatic visceral KS, except for that involving the oral cavity

          3. KS that appears to be improving after other therapy

          4. Inability to provide informed consent

          5. Patients requiring systemic therapy with ketoconazole or itraconazole

          6. Cytotoxic chemotherapy or other specific KS therapy (except for antiretroviral
             therapy) within the past 3 weeks.

          7. Prior therapy with BAY 43-9006

          8. Known hypersensitivity to BAY 43-9006

          9. Supraphysiologic doses of corticosteroids within 3 weeks

         10. Pregnancy (because of unknown potential for fetal malformation)

         11. Breast feeding (because of unknown potential for adverse infant developmental
             considerations)

         12. Past or present history of malignant tumors other than KS unless: a) in complete
             remission for greater than or equal to 1 year from the time a response was first
             documented; b) completely resected basal cell carcinoma; or c) in situ squamous cell
             carcinoma of the cervix or anus

         13. Evidence of severe or life-threatening infection within 2 weeks of entry into the
             study

         14. Elevated lipase greater than 2 times the ULN or amylase greater than 2 times the ULN
             (unless documented to be of non-pancreatic origin or associated with macroamylasemia

         15. Patients with any other abnormality that would be scored as a grade 3 or greater
             toxicity, except:

               -  lymphopenia

               -  direct manifestation of KS

               -  direct manifestation of HIV infection, except for neurologic or cardiac
                  manifestations.

               -  direct manifestation of HIV therapy, except for neurologic or cardiac
                  manifestations or those addressed elsewhere in the eligibility requirements or
                  that would be scored as grade 4.

               -  asymptomatic hyperuricemia

         16. Any condition that, in the opinion of the principal Investigator or Study Chairperson
             would preclude the inclusion of a patient into this research study.

         17. Patients must not have evidence of a bleeding diathesis.

         18. Patients must not be on therapeutic coagulation. Prophylactic anticoagulation (i.e.
             low dose warfarin) of venous or arterial access devices is allowed provided that the
             requirements for PT and PTT are met.

         19. Patients must not be taking cytochrome P450 enzyme-inducing antiepileptic drugs
             (phenytoin, carbamazepine, and Phenobarbital), rifampin, or St. Johns Wort.

         20. Patients are excluded if they have uncontrolled hypertension (diastolic blood pressure
             greater than 99 mm Hg or systolic blood pressure greater than 159 mm Hg)

         21. Patients are excluded if they have uncontrolled intercurrent illness including, but
             not limited to, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements.

         22. Patients must be able to understand and be willing to sign a written informed consent
             document, and express willingness and the ability to comply with the requirements of
             the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996 Aug;2(8):925-8.</citation>
    <PMID>8705864</PMID>
  </reference>
  <reference>
    <citation>Biggar RJ, Rosenberg PS, Cot√© T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer. 1996 Dec 11;68(6):754-8. Erratum in: Int J Cancer 1997 Mar 17;70(6):727.</citation>
    <PMID>8980179</PMID>
  </reference>
  <reference>
    <citation>Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000 Apr 6;342(14):1027-38. Review.</citation>
    <PMID>10749966</PMID>
  </reference>
  <verification_date>October 18, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <keyword>AIDS</keyword>
  <keyword>HIV</keyword>
  <keyword>Antiangiogenesis</keyword>
  <keyword>VEGF</keyword>
  <keyword>AIDS Malignancy</keyword>
  <keyword>Kaposi Sarcoma</keyword>
  <keyword>KS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

